The estimated Net Worth of Martin Godbout is at least $31.4 Tisíc dollars as of 4 March 2014. Martin Godbout owns over 300 units of Mirati Therapeutics Inc stock worth over $31,405 and over the last 11 years Martin sold MRTX stock worth over $0.
Martin has made over 2 trades of the Mirati Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Martin exercised 300 units of MRTX stock worth $4,284 on 4 March 2014.
The largest trade Martin's ever made was exercising 300 units of Mirati Therapeutics Inc stock on 4 March 2014 worth over $4,284. On average, Martin trades about 250 units every 39 days since 2013. As of 4 March 2014 Martin still owns at least 535 units of Mirati Therapeutics Inc stock.
You can see the complete history of Martin Godbout stock trades at the bottom of the page.
Martin's mailing address filed with the SEC is 9363 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza... a Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.
mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.
Mirati Therapeutics Inc executives and other stock owners filed with the SEC include: